News GeneTether Therapeutics Inc.

Equities

GTTX

CA37187D1087

Market Closed - Canadian Securities Exchange Other stock markets 12:49:38 25/06/2024 am IST			5-day change	1st Jan Change
0.05 ^CAD	0.00%		+150.00%	+25.00%

30/05	GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/03	5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
GeneTether Therapeutics Inc. Announces Fiscal Year 2023 Financial Results and Reports on Corporate Highlights	29/03	AQ
GeneTether Therapeutics Inc. Announces Third Quarter 2023 Financial Results	29/11	AQ
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11	CI
GeneTether Therapeutics Board Provides Shareholder Update	20/23/20	AQ
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	30/23/30	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	26/23/26	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
GeneTether Therapeutics Engages Gad Berdugo, Managing Partner of Explorium Capital LLC, as Advisor to Explore Strategic Alternatives for GeneTether Technology Platform	01/23/01	AQ
GeneTether Therapeutics Inc. Announces Fiscal Year 2022 Financial Results and Reports on Corporate Highlights	28/23/28	AQ
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
GeneTether Therapeutics Inc. Update - From the Desk of the CEO	31/23/31	AQ
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	30/23/30	CI
GeneTether Therapeutics Inc. Announces Commencement of Strategic Review Process	09/23/09	AQ
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	26/22/26	CI
GeneTether Therapeutics Inc. Announces Third Quarter 2022 Financial Results and Reports on Corporate Highlights	26/22/26	AQ
GeneTether Therapeutics Inc. Update - From the Desk of the CEO	25/22/25	AQ
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2022.	30/22/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News GeneTether Therapeutics Inc.

Equities

GTTX

CA37187D1087

Summary

Filters